Editorial Board · Reviewed Q2 2026

An editorial office
for the men told ‘it is just age.’

ProstaRemedy Press is a small American publishing imprint, composed in Wilmington, Delaware, and convened around a single editorial purpose: to publish a daily compendium for the prostate, founded on the published clinical literature rather than the assertion that the slow erosion of nightly sleep and daily quality of life is ‘simply what happens after fifty.’

A note on the imprint

The editorial rationale for the publication.

The literature on prostate-support botanicals is uneven, the standardisation between commercial extracts variable, and the marketing copy of the broader category persistently optimistic. The editorial board convened to assemble a compendium of the six actives with the most defensible published evidence base, each at the dose cited in the trials from which it is drawn.

The board reviewed the Cochrane and Lancet literature on Saw Palmetto, the European clinical-use literature on Pygeum, the trial base for Beta-Sitosterol and Stinging Nettle, and the EU and U.S. nutritional surveillance data on Zinc and Vitamin D3 in the midlife male population. Formulators in Germany and the Netherlands were consulted on extract standardisation.

The publication is, accordingly, a compendium of six actives at the published doses. No proprietary blends. No combination tablet of twenty fractional doses. The Materia Medica page sets out each entry, its standardisation, and the citations on file with the editorial office.

ProstaRemedy bottle
Editorial standards · Reviewed Q2 2026

Three standards the editorial board holds.

i.

Doses cited from published trials.

Each active in the compendium is dosed at the level used in the clinical trial from which it is cited. Where a published clinical dose cannot be included, the entry is not included.

ii.

Plant-derived.

No anabolics, no synthetic hormones, no scheduled substances, no precursors. Plant sterols, botanical extracts, and the two micronutrients — zinc and Vitamin D3 — in which the midlife male population is reliably under-replete.

iii.

The work, on file with the publisher.

Each lot is independently verified for active-compound content, heavy metals, and microbial purity. The Certificate of Analysis is on file with the publisher and is provided to readers on written request.

Composed in the United States

Composed in a GMP-certified U.S. facility.

Each edition of the publication is composed in deliberately small lots. Each lot is independently verified for active-compound content — specifically the standardised fatty-acid content of the Saw Palmetto extract — heavy metals, and microbial purity before release to the readership.

Raw materials are drawn from a short, audited list of European and Mediterranean botanical suppliers. The Saw Palmetto extract is sourced from a Spanish processor specialising in lipidosterolic extraction. Standardisation is verified at the ingredient level and again at the level of the finished edition.

On editorial position

On the writing of this publication.

The published literature on prostate-support botanicals is not uniformly affirmative. The trials are heterogenous, the meta-analyses conclude in differing directions, and the standardisation of the commercial extracts has, historically, varied enough to render cross-trial comparison less straightforward than the reader might suppose.

The editorial position of the publication is to set the picture out as the literature actually presents it — including the contested, the marginal, and the under-evidenced. The reader of this publication is, in the editorial board's experience, a careful researcher first and a customer second; the publication is written accordingly.

On the compendium

Read the Materia Medica.

Each entry, its standardisation, the published dose, and the trial from which the dose is drawn. The Materia Medica is the editorial board's catalogue of the publication.

Read the Materia Medica